Login to Your Account

Patient Death In ConjuChem Phase II Trial Halts Dosing

By Jennifer Boggs

Monday, July 17, 2006
ConjuChem Biotechnologies Inc. discontinued dosing in a Phase II trial of its growth hormone product, DAC:GRF in HIV lipodystrophy, pending an investigation into the death of a patient. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription